• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

永生人小梁网和非色素睫状上皮细胞中EP2和EP4前列腺素受体的功能药理学证据。

Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells.

作者信息

Crider J Y, Sharif N A

机构信息

Molecular Pharmacology Unit, Alcon Research, Ltd., Fort Worth, Texas 76134, USA.

出版信息

J Ocul Pharmacol Ther. 2001 Feb;17(1):35-46. doi: 10.1089/108076801750125658.

DOI:10.1089/108076801750125658
PMID:11322636
Abstract

The aim of these studies was to characterize the molecular pharmacology of the prostanoid receptors positively coupled to stimulation of adenylyl cyclase activity in immortalized human trabecular meshwork (TM-3) cells and to compare these results with that of the receptors in immortalized human nonpigmented epithelial (NPE) cells. In general, the TM-3 and NPE cells showed a similar profile with respect to their responses to various prostaglandin (PG) receptor agonists. The rank order of potency (EC50; means +/- SEM) for these compounds in the TM-3 cells was: PGE2 (124 +/- 21 nM) > 13,14-dihydro-PGE1 (430 +/- 110 nM) = PGE1 (522 +/- 345 nM) > 11-deoxy-PGE1 (1063 +/- 118 nM) = 16,16-dimethyl-PGE2 (1776 +/- 460 nM) = butaprost (1920 +/- 527 nM) >> PGD2 = PGI2 = PGF2alpha (n = 3 - 12). While the agonist profile indicated the presence of EP2 receptors, the effects of the EP4 receptor antagonists suggested the additional expression of EP4 receptors in both of these cells. Thus, the EP4 receptor antagonist, AH23848B, at a concentration of 30 microM, caused a dextral shift in the PGE2 concentration-response curves in both TM-3 and NPE cells coupled with a 20-28% decrease in the maximal response of PGE2, indicating apparent noncompetitive antagonism profiles. The antagonist potency of AH23848B in these cells was: Kb = 38.4 +/- 14.8 microM and 23.5 +/- 4.5 microM; -log Kb = 4.7. The other EP4 receptor antagonist, AH22921 (-log Kb = 4.1 - 4.7), was weaker than AH23848B. Taken together, these pharmacological studies have shown than TM-3 and NPE cells apparently contain functional EP2 and EP4 prostanoid receptors positively coupled to adenylyl cyclase.

摘要

这些研究的目的是表征在永生化人小梁网(TM - 3)细胞中与腺苷酸环化酶活性刺激正偶联的前列腺素受体的分子药理学,并将这些结果与永生化人非色素上皮(NPE)细胞中的受体结果进行比较。总体而言,TM - 3细胞和NPE细胞对各种前列腺素(PG)受体激动剂的反应显示出相似的特征。这些化合物在TM - 3细胞中的效价顺序(EC50;平均值±SEM)为:PGE2(124±21 nM)> 13,14 - 二氢 - PGE1(430±110 nM)= PGE1(522±345 nM)> 11 - 脱氧 - PGE1(1063±118 nM)= 16,16 - 二甲基 - PGE2(1776±460 nM)= 布他前列素(1920±527 nM)>> PGD2 = PGI2 = PGF2α(n = 3 - 12)。虽然激动剂特征表明存在EP2受体,但EP4受体拮抗剂的作用表明这两种细胞中还额外表达了EP4受体。因此,EP4受体拮抗剂AH23848B在浓度为30μM时,导致TM - 3细胞和NPE细胞中PGE2浓度 - 反应曲线向右移位,同时PGE2的最大反应降低20 - 28%,表明明显的非竞争性拮抗特征。AH23848B在这些细胞中的拮抗剂效价为:Kb = 38.4±14.8μM和23.5±4.5μM;-log Kb = 4.7。另一种EP4受体拮抗剂AH22921(-log Kb = 4.1 - 4.7)比AH23848B弱。综上所述,这些药理学研究表明,TM - 3细胞和NPE细胞显然含有与腺苷酸环化酶正偶联的功能性EP2和EP4前列腺素受体。

相似文献

1
Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells.永生人小梁网和非色素睫状上皮细胞中EP2和EP4前列腺素受体的功能药理学证据。
J Ocul Pharmacol Ther. 2001 Feb;17(1):35-46. doi: 10.1089/108076801750125658.
2
Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically defined EP2 receptor in human nonpigmented ciliary epithelial cells.前列腺素通过人非色素睫状上皮细胞中药理学定义的EP2受体刺激腺苷酸环化酶活性。
J Ocul Pharmacol Ther. 1998 Aug;14(4):293-304. doi: 10.1089/jop.1998.14.293.
3
Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization.中国仓鼠卵巢细胞中与腺苷酸环化酶正性偶联的内源性EP4前列腺素受体:药理学特性
Prostaglandins Leukot Essent Fatty Acids. 2000 Jan;62(1):21-6. doi: 10.1054/plef.1999.0120.
4
Adenylyl cyclase activity mediated by beta-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells.永生人小梁网和非色素睫状上皮细胞中β-肾上腺素能受体介导的腺苷酸环化酶活性
J Ocul Pharmacol Ther. 2002 Jun;18(3):221-30. doi: 10.1089/108076802760116142.
5
Identification of prostanoid receptors in rabbit non-pigmented ciliary epithelial cells.兔非色素睫状上皮细胞中前列腺素受体的鉴定。
Exp Eye Res. 1996 May;62(5):491-8. doi: 10.1006/exer.1996.0059.
6
Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.前列腺素E2抑制脂多糖诱导人血单核细胞产生肿瘤坏死因子-α 时作用的前列腺素类受体的特性研究。
Br J Pharmacol. 1997 Sep;122(1):149-57. doi: 10.1038/sj.bjp.0701360.
7
Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells.人睫状上皮细胞和睫状肌细胞中EP2、EP4和FP受体的检测。
Biochem Pharmacol. 1997 May 9;53(9):1249-55. doi: 10.1016/s0006-2952(97)00011-7.
8
Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle.前列腺素对牛眼小梁网和睫状肌收缩性的影响。
Exp Eye Res. 1997 Mar;64(3):447-53. doi: 10.1006/exer.1996.0224.
9
Pharmacological and molecular biological (RT-PCR) characterization of functional TP prostanoid receptors in immortalized human non-pigmented ciliary epithelial cells.永生化人非色素睫状上皮细胞中功能性TP前列腺素受体的药理学和分子生物学(RT-PCR)特性分析
J Ocul Pharmacol Ther. 2002 Apr;18(2):141-62. doi: 10.1089/108076802317373905.
10
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.眼内压降低的FP前列腺素(PG)类似物:PG受体亚型结合亲和力和选择性,以及在培养细胞中对FP和其他PG受体的激动剂效力。
J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. doi: 10.1089/108076803322660422.

引用本文的文献

1
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.近期获批的用于降低和控制眼压以减少高眼压症和青光眼患者视力丧失的药物。
Pharmaceuticals (Basel). 2023 May 26;16(6):791. doi: 10.3390/ph16060791.
2
Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome.针对小鼠中不同前列腺素受体的眼部治疗在眼压和视神经脂质组方面表现出改变。
J Ocul Pharmacol Ther. 2023 Oct;39(8):541-550. doi: 10.1089/jop.2023.0006. Epub 2023 Jun 2.
3
Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma.
前列腺素类似物在青光眼治疗中的临床药理学与药物遗传学
Front Pharmacol. 2022 Oct 12;13:1015338. doi: 10.3389/fphar.2022.1015338. eCollection 2022.
4
Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.治疗高眼压症和青光眼的治疗药物与设备,以及神经保护和细胞保护疗法的必要性。
Front Pharmacol. 2021 Sep 17;12:729249. doi: 10.3389/fphar.2021.729249. eCollection 2021.
5
Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.抗过敏(依美斯汀;帕坦洛/帕迪特/帕泽奥)和抗青光眼(曲伏前列素;辛布林扎)眼科药物的研发至上市,以及新型药理学工具如AL - 8810的产生。
ACS Pharmacol Transl Sci. 2020 Nov 5;3(6):1391-1421. doi: 10.1021/acsptsci.0c00137. eCollection 2020 Dec 11.
6
Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.前列腺素 FP 受体拮抗剂:发现、药理学特性和治疗用途。
Br J Pharmacol. 2019 Apr;176(8):1059-1078. doi: 10.1111/bph.14335. Epub 2018 Jun 7.